|
|
Protective effect of oligomeric proanthocyanidins on dextran sulfate sodium induced ulcerative colitis in mice |
LV Xiaonan, DONG Zheng, LI Chunjin, CAO Yipo, LI Ying, MA Bo, YAO Min |
No.1 Medical Department, Tianjin Municipal Corps Hospital, Chinese People’s Armed Police Force, Tianjin 300162, China |
|
|
Abstract Objective To investigate the therapeutic effect of oligomeric proanthocyanidins (OPC) against ulcerative colitis (UC) induced by dextran sulfate sodium (DSS) in mice and explore the protective mechanism of OPC.Methods 32 male C57 mice were fed with 2.5% DSS to establish a UC model, which were randomly divided into the model group, treatment control group (mesalazine, 500 mg/kg), low dose group (OPC, 500 mg/kg) and high dose group (OPC, 1000 mg/kg), with 8 mice in each group. At the same time, another 8 male C57 mice were used as the control group and fed with normal water. After 7 days, the mice were sacrificed to evaluate the disease activity index (DAI), observe the pathological changes and evaluate the CMDI, detect the level of serum IL-10 and assay the activity of myeloperoxidase (MPO) in the colon.Results Compared with the normal control group, the DAI score increased significantly, the length of the colon decreased, the colonic mucosa became thinner,the epithelium was exfoliated and inflammatory cells were infiltrated in UC model groups. The level of serum IL-10 decreased significantly, and the activity of MPO improved significantly (P<0.05). Compared with the model control group, the indexes of each group significantly improved (P<0.05), but there was no significant difference between the high dose group and the treatment control group.Conclusions In mice with UC induced by DSS, OPC may help ameliorate DAI and improve the pathological morphology of colon tissue of mice by reducing oxidative stress and inhibiting inflammatory reactions.
|
Received: 10 January 2020
|
|
|
|
|
[1] |
黄 凯,王大宁,彭 朋,等.高强度间歇运动加重溃疡性结肠炎小鼠炎性反应的影响[J].武警医学,2019,30(5):416-419.
|
[2] |
Ungaro R, Mehandru S, Allen P B, et al. Ulcerative colitis[J].Lancet, 2017, 389(10080): 1756-1770.
|
[3] |
Ko C W, Singh S, Feuerstein J D, et al. AGA clinical practice guidelines on the management of mild-to-moderate ulcerative colitis[J].Gastroenterology, 2019, 156(3):748-764.
|
[4] |
葛文松.炎性反应性肠病治疗目标的演变[J].中华消化病与影像杂志(电子版),2019,9(5):199-202.
|
[5] |
吕晓楠,王 霞,朱 江,等. 低聚原花青素对佛波酯诱导的Caco-2细胞损伤的影响[J]. 武警后勤学院学报(医学版),2015,25(2):89-91.
|
[6] |
Cádiz M L, Borrás L I, Lozano S J, et al. Cocoa and grape seed byproducts as a source of antioxidant and anti-inflammatory proanthocyanidins[J].Int J Mol Sci, 2017, 18(2):376.
|
[7] |
Yang L,Xian D,Xiong X,et al.Proanthocyanidins against oxidative stress:from molecular mechanisms to clinical applications[J].Biomed Res Int,2018,12(3):8584136.
|
[8] |
Nikkhah B M,Darabi Z,Agah S, et al. The effects of nigella sativa on quality of life, disease activity index, and some of inflammatory and oxidative stress factors in patients with ulcerative colitis[J]. Phytotherapy research PTR,2019, 33(4):1027-1032.
|
[9] |
CAO S Y,YE S J ,WANG W W, et al. Progress in active compounds effective on ulcerative colitis from Chinese medicines[J]. Chi J Nat Med,2019,2:81-102.
|
[10] |
Li J, Lyu H, Yang H, et al. Preoperative corticosteroid usage and hypoalbuminemia increase occurrence of short-term postoperative complications in chinese patients with ulcerative colitis[J].Chin Med J (Engl), 2016, 129(4):435-441.
|
[11] |
Sehgal P,Colombel J F,Aboubakr A, et al. Systematic review: safety of mesalazine in ulcerative colitis[J]. Aliment Pharmacol Ther, 2018, 47(12):1597-1609.
|
[12] |
全 帅,吕开原,李新宇,等.低聚葡萄籽原花青素对葡聚糖硫酸钠诱导的小鼠溃疡性结肠炎的影响及作用机制[J].中草药,2020,51(1):149-156.
|
[13] |
吕晓楠. 低聚原花青素对抗溃疡性结肠炎的作用及其机制研究[D]. 天津: 武警后勤学院, 2014.
|
[14] |
Zhang D, Wei C, Yao J, et al. Interleukin-10 gene-carrying bifidobacteria ameliorate murine ulcerative colitis by regulating regulatory T cell/T helper 17 cell pathway[J].Exp Biol Med (Maywood), 2015, 240(12):1622-1629.
|
[15] |
Jiang X E, Yang S M, Zhou X J, et al. Effects of mesalazine combined with bifid triple viable on intestinal flora, immunoglobulin and levels of cal, MMP-9, and MPO in feces of patients with ulcerative colitis[J]. Eur Rev Med Pharmacol Sci, 2020, 24(2):935-942.
|
|
|
|